Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00VPU
|
||||
| Former ID |
DCL000993
|
||||
| Drug Name |
SLV-323
|
||||
| Indication | Irritable bowel syndrome; Chemo therapy induced emesis; Gastric motility disorder [ICD9: 536.8, 564.1, 787; ICD10:K30, K58, R11] | Discontinued in Phase 1 | [1] | ||
| Company |
Solvay
|
||||
| Target and Pathway | |||||
| Target(s) | Substance-P receptor | Target Info | Modulator | [1] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Measles | |||||
| PANTHER Pathway | CCKR signaling map ST | ||||
| Reactome | G alpha (q) signalling events | ||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Spinal Cord Injury | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.